LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

Search

Corcept Therapeutics Inc

Gesloten

SectorGezondheidszorg

82.14 0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

78.59

Max

82.88

Belangrijke statistieken

By Trading Economics

Inkomsten

-16M

19M

Verkoop

13M

208M

K/W

Sectorgemiddelde

100.345

76.798

Winstmarge

9.323

Werknemers

500

EBITDA

-11M

16M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+54.4% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

9.2B

Vorige openingsprijs

81.24

Vorige sluitingsprijs

82.14

Nieuwssentiment

By Acuity

47%

53%

152 / 374 Rangschikking in Healthcare

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 dec 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17 dec 2025, 23:20 UTC

Winsten

Correction to Micron Logs Sales Jump Article

17 dec 2025, 23:07 UTC

Winsten

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17 dec 2025, 21:37 UTC

Winsten

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17 dec 2025, 23:53 UTC

Marktinformatie

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17 dec 2025, 23:06 UTC

Acquisities, Fusies, Overnames

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17 dec 2025, 23:05 UTC

Acquisities, Fusies, Overnames

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17 dec 2025, 23:04 UTC

Acquisities, Fusies, Overnames

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17 dec 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17 dec 2025, 22:56 UTC

Acquisities, Fusies, Overnames

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17 dec 2025, 22:55 UTC

Acquisities, Fusies, Overnames

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17 dec 2025, 22:49 UTC

Marktinformatie

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17 dec 2025, 21:58 UTC

Winsten

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 dec 2025, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 dec 2025, 21:46 UTC

Winsten

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17 dec 2025, 21:20 UTC

Winsten

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 dec 2025, 21:10 UTC

Winsten

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17 dec 2025, 21:05 UTC

Winsten

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17 dec 2025, 21:04 UTC

Winsten

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17 dec 2025, 21:04 UTC

Winsten

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17 dec 2025, 21:03 UTC

Winsten

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17 dec 2025, 21:03 UTC

Winsten

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17 dec 2025, 21:03 UTC

Winsten

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17 dec 2025, 21:02 UTC

Winsten

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17 dec 2025, 21:01 UTC

Winsten

Micron Technology 1Q Rev $13.64B >MU

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

54.4% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 125.25 USD  54.4%

Hoogste 145 USD

Laagste 95 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Sentiment

By Acuity

152 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat